Effect of telmisartan and enalapril on ventricular remodeling and kidney prognosis of patients with coronary artery disease complicated with diabetic nephropathy

Shearer F, Lang CC and Struthers AD: Renin-angiotensin-aldosterone system inhibitors in heart failure. Clin Pharmacol Ther. 94:459–467. 2013. View Article : Google Scholar : PubMed/NCBI

Ma TK, Kam KK, Yan BP and Lam YY: Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: Current status. Br J Pharmacol. 160:1273–1292. 2010. View Article : Google Scholar : PubMed/NCBI

DeLeon-Pennell KY, Tian Y, Zhang B, Cates CA, Iyer RP, Cannon P, Shah P, Aiyetan P, Halade GV, Ma Y, et al: CD36 is a matrix metalloproteinase-9 substrate that stimulates neutrophil apoptosis and removal during cardiac remodeling. Circ Cardiovasc Genet. 9:14–25. 2016. View Article : Google Scholar : PubMed/NCBI

Qian Q, Manning DM, Ou N, Klarich MJ, Leutink DJ, Loth AR and Lopez-Jimenez F: ACEi/ARB for systolic heart failure: Closing the quality gap with a sustainable intervention at an academic medical center. J Hosp Med. 6:156–160. 2011. View Article : Google Scholar : PubMed/NCBI

Padda RS, Shi Y, Lo CS, Zhang SL and Chan JS: Angiotensin-(1–7): A novel peptide to treat hypertension and nephropathy in diabetes? J Diabetes Metab. 6:1–6. 2015.

Lee SH, Yoo TH, Nam BY, Kim DK, Li JJ, Jung DS, Kwak SJ, Ryu DR, Han SH, Lee JE, et al: Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions. Am J Physiol Renal Physiol. 297:F1381–F1390. 2009. View Article : Google Scholar : PubMed/NCBI

Cha DR, Kang YS, Han SY, Jee YH, Han KH, Kim HK, Han JY and Kim YS: Role of aldosterone in diabetic nephropathy. Nephrology (Carlton). 10:(Suppl). S37–S39. 2005. View Article : Google Scholar : PubMed/NCBI

de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE and Brenner BM: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int. 65:2309–2320. 2004. View Article : Google Scholar : PubMed/NCBI

van de Wal RM, Plokker HW, Lok DJ, Boomsma F, van der Horst FA, van Veldhuisen DJ, van Gilst WH and Voors AA: Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol. 106:367–372. 2006. View Article : Google Scholar : PubMed/NCBI

Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, et al: HEAAL Investigators: Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): A randomised, double-blind trial. Lancet. 374:1840–1848. 2009. View Article : Google Scholar : PubMed/NCBI

Voors AA and van Veldhuisen DJ: Role of angiotensin receptor blockers in patients with left ventricular dysfunction: Lessons from CHARM and VALIANT. Int J Cardiol. 97:345–348. 2004. View Article : Google Scholar : PubMed/NCBI

Dickstein K and Kjekshus J: OPTIMAAL Steering Committee of the OPTIMAAL Study Group: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 360:752–760. 2002. View Article : Google Scholar : PubMed/NCBI

Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, et al: Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 361:40–51. 2009. View Article : Google Scholar : PubMed/NCBI